Repligen/RGEN

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Repligen

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.

Ticker

RGEN

Sector

Healthcare

Trading on

NASDAQ

Industry

Life Sciences Tools and Services

Headquarters

Waltham, United States

Employees

-

Repligen Metrics

BasicAdvanced
$6.7B
Market cap
453.98
P/E ratio
$0.26
EPS
1.03
Beta
-
Dividend rate
$6.7B
1.03
6.354
5.027
33.415
37.437
1.75%
0.60%
0.76%
453.98
11.03
3.4
11.22
61.16
-21.90%
-91.02%
11.95%
-43.35%

What the Analysts think about Repligen

Analyst Ratings

Majority rating from 13 analysts.
Buy

Repligen Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
1.32% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$151M
-2.83%
Net income
$2M
-107.87%
Profit margin
1.32%
-108.09%

Repligen Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 7.18%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.53
$0.23
$0.33
$0.28
-
Expected
$0.48
$0.17
$0.33
$0.30
$0.33
Surprise
11.52%
38.68%
1.37%
-7.18%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Repligen stock?

Repligen (RGEN) has a market cap of $6.7B as of July 04, 2024.

What is the P/E ratio for Repligen stock?

The price to earnings (P/E) ratio for Repligen (RGEN) stock is 453.98 as of July 04, 2024.

Does Repligen stock pay dividends?

No, Repligen (RGEN) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Repligen dividend payment date?

Repligen (RGEN) stock does not pay dividends to its shareholders.

What is the beta indicator for Repligen?

Repligen (RGEN) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Repligen stock

Buy or sell Repligen stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing